Lack of Metformin Effects on Different Molecular Subtypes of Breast Cancer under Normoglycemic Conditions: An in vitro Study |
Sadighi, Sanambar
(Cancer Research Center, Cancer Institute of Iran)
Amanpour, Saeid (Cancer Models Research Center, Cancer Institute of Iran) Behrouzi, Bita (Cancer Research Center, Cancer Institute of Iran) Khorgami, Zhinoos (Iranian Tissue Bank Research and Preparation Center) Muhammadnejad, Samad (Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences) |
1 | Szewczyk M, Richter C, Briese V, et al (2012). A retrospective in vitro study of the impact of anti-diabetics and cardioselective pharmaceuticals on breast cancer. Anticancer Res, 32, 2133-8. |
2 | Liu H, Scholz C, Zang C, et al (2012). Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res, 32, 1627-37. |
3 | Peairs KS, Barone BB, Snyder CF, et al (2011). Diabetes mellitus and breast cancer outcomes: a systematic review and metaanalysis. J Clin Oncol, 29, 40-6. DOI ScienceOn |
4 | Plumb JA, Milroy R, Kaye SB (1989). Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res, 49, 4435-40. |
5 | Scarpello JH, Howlett HC (2008). Mettformin therapy and clinical uses. Diab Vasc Dis Res, 5, 157-67. DOI ScienceOn |
6 | Viollet B, Guigas B, Sanz Garcia N, et al (2012). Cellular and molecular mechanisms of metformin: an overview. Clin Sci, 122, 253-70. DOI |
7 | Wang Y, Zhang MX, Duan XY, et al (2011). Effects of antidiabetic drug metformin on human breast carcinoma cells with different estrogen receptor expressing in vitro. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 27, 253-6. |
8 | Wolf I, Sadetzki S, Catane R, et al (2005). Diabetes mellitus and breast cancer. Lancet Oncol, 6, 103-11. DOI ScienceOn |
9 | Zakikhani M, Dowling R, Fantus IG, et al (2006). Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res, 66, 10269-73. DOI ScienceOn |
10 | Evans JM, Donnelly LA, Emslie-Smith AM, et al (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ, 330, 1304-5. DOI ScienceOn |
11 | Cufi S, Corominas-Faja B, Vazquez-Martin A, et al (2012). Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget, 3, 395-8. |
12 | Del Barco S, Vazquez-Martin A, Cufi S, et al (2011). Metformin: multi-faceted protection againist cancer. Oncotarget, 2, 896-917. |
13 | Dowling RJ, Zakikhani M, Fantus IG, et al (2007) Metformin inhibits mammalian target of rapamycin-dependent translation inhibition in breast cancer cells. Cancer Res, 67, 10804-12. DOI ScienceOn |
14 | Goodwin PJ, Stambolic V, Lemieux J, et al (2011). Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat, 126, 215-20. DOI |
15 | Goodwin PJ, Stambolic V (2011). Metformin, cancer risk, and prognosis. In "ASCO Educational Book". ASCO University, pp 42-5. |
16 | Goodwin PJ, Ligibel JA, Stambolic V (2009). Metformin in breast cancer: time for action. J Clin Oncol, 27, 3271-3. DOI ScienceOn |
17 | Hirsch HA, Iliopoulos D, Struhl K (2013). Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci USA, 110, 972-7. DOI |
18 | Lipscombe LL, Goodwin PJ, Zinman B, et al (2008). The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat, 109, 389-95. DOI ScienceOn |
19 | Liu B, Fan Z, Edgerton SM, et al (2011). Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Cell Cycle, 10, 2959-66. DOI |
20 | Bowker SL, Majumdar SR, Veugelers P, et al (2006). Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care, 29, 254-8. DOI ScienceOn |
21 | Chen TW, Liang YN, Feng D, et al (2013). Metformin inhibits proliferation and promotes apoptosis of HER2 positive breast cancer cells by downregulating HSP90. J BUON, 18, 51-6. |
22 | Wild S, Roglic G, Green A, et al (2004). Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 27, 1047-53. DOI ScienceOn |